さらに、強力な標的タンパク質分解型創薬基盤を有する子会社Cullgenが、NASDAQ上場企業Pulmatrixとの合併を発表し、この合併は2025年に完了し、上場をはたす予定です。このように、パズルのピースが次々とはまる中で、当社グループは、日本、米国、中国に拠点をおき、グローバル中堅製薬企業への道を着実に歩んでいます。Dear Shareholders, employees, and all stakeholders,
The year 2024 has become a historic year for the GNI Group. When we changed our company name from GNI to GNI Group in 2011, a vision was drawn of how our group would evolve from a biotech venture company into a biopharmaceutical company with multiple subsidiaries and affiliates collaborating across various fields such as drug discovery, development, manufacturing, and commercialization. The organizational structure that has been realized is believed to be an ideal model for achieving sustained success in the Asian market and a rapidly changing world. This dream has finally come true in 2024.
In 2024, our consolidated subsidiary Peking Continent spent its first year listed on NASDAQ. After the listing, an enormous amount of effort was devoted to governance and compliance. Additionally, we invested in Japan Asia Investment Co., Ltd., which is a listed company on the Tokyo Stock Exchange, enabling our group to continue advancing into various industry sectors.
Furthermore, our subsidiary Cullgen, which has a strong targeted protein degradation drug discovery platform, announced a merger with NASDAQ-listed Pulmatrix, which is expected to be completed in 2025 and lead to a new listing. In this way, as the pieces of the puzzle are falling into place, our group is steadily advancing toward becoming a Global medium-sized pharmaceutical company based in Japan, the USA, and China.
While looking forward to a prosperous 2025, there is excitement about the expansion of the biomaterials (Medical Devices) sector led by Berkely Advanced Biomaterials. By adding investments in newly acquired subsidiaries in the same industry and sales channels in China, this sector is strategically aimed to grow into the third strong pillar of our group, achieving over 15 billion yen in revenue and high profitability in the next two to three years. Medical Devices will play another important role in the future growth and stability of the group.
The year 2025 is expected to bring numerous milestones, including the potential NDA (New Drug Application) for the liver fibrosis treatment drug F351, advancements in clinical development of cancer drugs by Cullgen, and the expansion of our group's business base in Japan. With the support of competent and experienced management dedicated to the business and all stakeholders, it is believed that growth will accelerate even further beyond 2025. Our group has a proud history as a pioneer that has achieved commercial success in the biotech industry and established an excellent Revenue Model. We promise to continue evolving into a Global medium-sized pharmaceutical company that brings benefits to patients, Shareholders, employees, and all relevant parties.
January 6, 2025
GNI Group, Inc.
Director, Representative Executive Officer, and CEO.
In Luo.
